Sufficient RAGE targeting established with 64Cu-Cy5-G4-CML in LNCaP and DU145 prostate cancer cells, mice xenografts and human samples, confirming the feasibility of RAGE-targeted cancer imaging with AGE-conjugated nanoparticles. The gene discussed is AGER; the disease is prostate carcinoma.